

## Ken Rollins

Partner in Charge – San Diego

---



krollins@cooley.com

+1 858 550 6136

San Diego

Capital Markets  
Emerging Companies  
Mergers and Acquisitions  
Public Companies  
Venture Capital  
Life Sciences  
Technology  
Shareholder Activism

---

Ken represents emerging and late-stage private companies and public companies in a wide range of corporate and securities matters, including private financings, public offerings, M&A, tender offers, strategic collaborations, commercial agreements, corporate governance matters, and employment and compensation arrangements. He also advises venture capital firms in connection with financings and other transactions. In the last five years, he has represented companies and venture capitalists in more than 50 private financings and helped clients achieve an aggregate of \$6 billion+ in successful exit transactions. Ken serves as both partner in charge and head of the corporate practice for Cooley's San Diego office.

Ken is counsel to companies and venture funds in diverse industries, with a focus in life sciences, medtech and technology. His clients range from startups to public companies with hundreds of millions of dollars in annual revenue – and include companies such as ARS Pharmaceuticals, Avalon Ventures, BlueNalu, Design Therapeutics, Epigenomics, Janux Therapeutics, Regulus Therapeutics and TVC Capital.

**Ken's representative transactions include advising:**

- Drata – \$100 million Series B financing and \$200 million Series C financing
- Design Therapeutics – \$240 million initial public offering and \$125 million Series B financing
- Janux Therapeutics – \$194 million IPO and \$125 million Series B financing
- Silverback Therapeutics – \$242 million IPO and subsequent merger with ARS Pharmaceuticals
- VelosBio – \$2.75 billion sale to Merck
- Synthorx – \$131 million IPO, \$63 million Series C financing and \$2.5 billion sale to Sanofi
- Tocagen – \$98 million IPO
- Auspex – \$96.6 million IPO and \$3.5 billion sale to Teva Pharmaceutical Industries
- Pharmatek Laboratories' sale to Catalent
- RainTree Oncology Services Corporation's sale to Cardinal Health
- Elcelyx Therapeutics – \$40 million Series E financing
- AltheaDx – \$27 million Series D financing
- Portfolium – Series A financing and subsequent \$43 million sale to Instructure

In addition to serving as head of Cooley's San Diego business department, Ken serves on the boards of EvoNexus, a startup technology incubator located in San Diego, and Clarity Foundation, which strives to

improve treatment options for ovarian cancer patients.

## Education

University of Virginia School of Law  
JD, 2002

Southern Utah University  
BA, 1998

## Admissions & Credentials

California